STOCK TITAN

Cannabis Bioscience files NT 10-Q with preliminary Q4 figures

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
NT 10-Q

Rhea-AI Filing Summary

Cannabis Bioscience International Holdings (CBIH) filed a Notification of Late Filing (Form 12b-25) for its Form 10-Q for the period ended August 31, 2025, citing that the financial information for the quarter could not be analyzed and completed on a timely basis.

The company provided preliminary estimates indicating a smaller loss from operations of approximately $66,000 versus $97,604 a year earlier. Estimated revenue is about $36,000 compared with $178,887, and estimated gross profit is about $28,000 versus $170,525 for the prior-year quarter. Estimated total operating expenses are approximately $94,000, down from $268,129, reflecting substantial decreases in general and administrative expenses, professional fees, share-based compensation, and rent. Estimated net loss is about $42,511, compared with $76,305 in the prior year.

Positive

  • None.

Negative

  • None.

Insights

Late NT 10-Q with preliminary metrics: lower revenue, narrower loss.

CBIH filed an NT 10-Q, indicating its quarterly financials weren’t finalized in time. The narrative cites difficulty completing analysis, a common administrative delay. The company also shared preliminary figures to frame expected results.

The estimates show a sharp year-over-year revenue decline to $36,000 with gross profit of $28,000, but materially lower operating expenses of $94,000. This yields a smaller estimated net loss of $42,511 versus $76,305.

Actual results depend on the finalized 10-Q. The filing’s preliminary data suggest cost reductions offset part of the revenue drop; the precise impact will be clear once the report is filed.

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

 

FORM 12b-25

NOTIFICATION OF LATE FILING

 

SEC File No. 333-146758

 

(Check One)     ☐ Form 10-K       ☐ Form 20-F     ☐ Form 11-K     ☒ Form 10-Q      ☐ Form 10-D     ☐ Form N-CEN      ☐ Form N-CSR

 

For Period Ended: August 31, 2025

 

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

 

For the Transition Period Ended: ________________________

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

 

PART I - REGISTRANT INFORMATION

 

CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.

Full Name of Registrant

 

6201 Bonhomme Road, Suite 435N

Address of Principal Executive Office (Street and Number)

 

Houston, TX 77036

City, State, Zip Code

 

 

 

 

 

 

 

 

 

 

   

 

 

PART II - RULES 12b-25 (b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

    (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
  (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
    (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

 

PART III - NARRATIVE

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof could not be filed within the prescribed time period.

 

The financial information to be contained in the Registrant's Quarterly Report on Form 10-Q for the year ended August 31, 2025, cannot be analyzed and completed on a timely basis.

 

 

PART IV - OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification:

 

Dante Picazo   214   733-0868
(Name)   (Area Code)   (Telephone No.)

 

(2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). ☒ Yes ☐ No

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes No

 

Loss from operations for the three months ended August 31, 2025, is estimated to be approximately $66,000, compared with loss from operations of $97.604 for the three months ended August 31, 2024. Revenues and gross profit for the three months ended August 31, 2025, are estimated to be approximately $36,000 and $28,000, respectively, compared with $178,887 and $170,525, respectively, for the three months ended August 31, 2024. Total operating expenses for the three months ended August 31, 2025, are estimated to be approximately $94,000, compared with $268,129 for the three months ended August 31, 2024. Operating expenses were affected principally by substantial decreases in general and administrative expenses, professional fees, share-based compensation and rent. Net loss for the three months ended August 31, 2025, is expected to be approximately $42,511, compared with $76,305 for the three months ended August 31, 2024.

 

 

 

 

 

 2 

 

 

CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Date: October 15, 2025   By:

/s/ Dante Picazo                   

Chief Executive Officer

(principal executive officer and

principal accounting officer)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 

 

FAQ

What did CBIH (CBIH) file?

CBIH filed a Form 12b-25 (NT 10-Q), notifying a delay in filing its Quarterly Report for the period ended August 31, 2025.

Why is CBIH’s 10-Q delayed?

The company stated the financial information for the quarter could not be analyzed and completed on a timely basis.

What are CBIH’s estimated Q4 revenue and gross profit?

Estimated revenue is about $36,000 and estimated gross profit is about $28,000 for the three months ended August 31, 2025.

How do CBIH’s operating expenses compare year over year?

Estimated operating expenses are about $94,000 versus $268,129 a year earlier, reflecting substantial decreases across several expense categories.

What is CBIH’s estimated net loss for the quarter?

Estimated net loss is about $42,511, compared with $76,305 for the same quarter last year.

Did CBIH indicate significant changes in results of operations?

The company provided estimates showing lower revenue and expenses, with a narrower net loss versus the prior-year quarter.
Cannabis Bioscience International Holdings Inc

OTC:CBIH

CBIH Rankings

CBIH Latest News

CBIH Latest SEC Filings

CBIH Stock Data

5.47M
4.84B
52.8%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Houston